Management of HIV-associated cryptococcal disease in South Africa by Govender, N.P & Dlamini, S
CONTINUING MEDICAL EDUCATION
    December 2014, Vol. 104, No. 12
It is appropriate that management of HIV-associated 
cryptococcal meningitis (CM) is included as a topic in 
this edition of CME because the opportunistic fungal 
pathogen, Cryptococcus neoformans, remains the 
most common cause of adult meningitis in southern 
Africa.[1,2] In developed countries, widespread access to antiretroviral 
therapy (ART) during the 1990s was associated with a concomitant 
decline in the incidence of CM.[3,4] However, the large HIV epidemic 
in South Africa (SA), coupled with the delayed introduction of ART 
into the public sector for patients with advanced HIV disease and 
defaulting of ART, has led to a relatively smaller impact of ART 
on the incidence of CM.[5,6] The incidence of laboratory-confirmed 
disease in Gauteng Province decreased from 24 to 16 reported cases 
of CM per 100 000 persons in the general population during 2006 - 
2013.[6] However, this is still higher than the 2002 baseline incidence 
of 15 reported cases of CM per 100  000 persons (N P Govender – 
unpublished data). Furthermore, there have been important recent 
developments. A simple cryptococcal antigen (CrAg) lateral flow 
assay (LFA) is now commercially available for more accurate, rapid 
and potentially point-of-care diagnosis of CM and asymptomatic 
antigenaemia.[7,8]  New information is also available on a CrAg screen-
and-treat intervention to prevent CM-related deaths, including cost-
effectiveness data.[9] Recently published clinical trials have highlighted 
the most efficacious antifungal agents for induction-phase treatment 
and optimal timing of ART after a first diagnosis of CM.[10,11] 
Prevention of CM 
In routine-care settings in sub-Saharan Africa, the 10-week mortality 
associated with CM is high, even with prompt, appropriate antifungal 
treatment and correctly timed initiation of ART. CM accounted for 13 - 18% 
of all deaths in four Ugandan cohorts of HIV-infected persons and 44% 
of deaths in a cohort of SA miners.[12-16] Although it is well recognised 
that early diagnosis of HIV infection and initiation of ART before 
the development of AIDS is the most important way to prevent CM, 
only half of patients in sub-Saharan Africa know their HIV infection 
status and only 32% are on ART.[17] Furthermore, a large proportion 
of patients present to HIV care late.[18,19] Consequently, two focused 
strategies have been explored to prevent CM among those at highest 
risk of disease. Primary antifungal prophylaxis is not routinely 
recommended for patients with a CD4+ count <100  cells/µL unless 
a prolonged delay in ART initiation is anticipated.[20] An alternative 
is a screen-and-treat intervention for patients with a CD4+ count 
<100 cells/µL, using CrAg screening of serum or plasma followed 
by targeted pre-emptive fluconazole therapy for those testing CrAg-
positive, provided they do not have CM; this is currently being 
implemented in SA.[21] The latter intervention is feasible because 
asymptomatic persons with subclinical cryptococcal disease can 
be detected from 3 weeks to more than 3 months prior to the 
development of symptomatic CM, using a simple blood test.[12] The 
screen-and-treat intervention has been shown to be cost-effective 
in several settings.[9,22] Based on recent estimates, approximately 
2% of asymptomatic SA persons with a CD4+ count <100 cells/µL 
and no prior diagnosis of CM have cryptococcal antigenaemia.[23] 
The updated Southern African HIV Clinicians Society (SAHIVCS) 
guidelines recommend that HIV-infected ART-naive adults with a 
CD4+ count <100 cells/µL should be screened for cryptococcal disease 
before ART is started and screening for cryptococcal antigenaemia 
should occur by reflex laboratory or clinician-initiated testing (Fig. 1).[24] 
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Patients with a prior diagnosis of CM need not be screened. Those 
with a new positive CrAg blood test have disseminated cryptococcal 
disease and should be specifically evaluated for symptoms/signs of 
meningitis, i.e. headache and confusion. Patients with symptoms/
signs should be referred for lumbar puncture (LP) to exclude CM. 
If CM is confirmed on LP, they should be managed in hospital (for 
at least 2 weeks) and ART deferred for 4 - 6 weeks. CrAg-positive 
patients without symptoms/signs may be offered an LP, if this is 
immediately accessible, to exclude subclinical meningitis. For CrAg-
positive patients without suspected meningitis, oral fluconazole 
(800 mg for 2 weeks, followed by standard consolidation and 
maintenance treatment) is recommended, also for patients with an 
LP that is cryptococcal test negative. For those without symptoms/
signs or evidence of meningitis, ART should be started 2 weeks after 
antifungal therapy is initiated. 
Antifungal treatment for CM 
By convention, antifungal treatment for HIV-associated CM among 
non-pregnant adults is divided into three phases over a minimum 
period of 1 year: a 2-week induction phase, including intravenous 
amphotericin B deoxycholate 1 mg/kg/d as a backbone; an 8-week 
consolidation phase with fluconazole 400 mg/d; and a maintenance 
phase with fluconazole 200 mg/d (until the CD4+ count is 
>200 cells/µl for 6 months on ART and the HIV-1 viral load is 
suppressed).[24] The fungicidal agent amphotericin B should be 
paired with another antifungal agent to maximise cerebrospinal 
fluid (CSF) fungal clearance during the induction phase (Table 1). A 
recently published Phase III three-arm randomised controlled trial 
confirmed that the combination of conventional amphotericin B and 
oral flucytosine for 2 weeks was associated with a 39% reduction 
in 10-week mortality and more rapid CSF fungal clearance than 
amphotericin B monotherapy among HIV-infected patients with 
CM.[10] However, registration of flucytosine with the South African 
Medicines Control Council has not been maintained, the cost of 
the imported medicine is currently prohibitive and this agent is not 
included in the South African Essential Medicines List for hospitals.[25] 
In line with guidelines from the World Health Organization (WHO), 
SAHIVCS guidelines recommend that amphotericin B be paired with 
high-dose oral fluconazole (800 mg/d) during the 2-week induction 
phase.[20,24] Although fluconazole is fungistatic and less effective 
in combination than flucytosine, this recommendation is made 
for two reasons. Firstly, data from a Phase III trial show superior 
CSF fungal clearance for the combination of amphotericin B 
and fluconazole than for amphotericin B monotherapy, and 
data from two trials show a non-significant reduction in mortality 
and neurological morbidity endpoints.[10,26] Secondly, fluconazole 
is well tolerated and widely accessible to SA clinicians for the 
management of CM through the long-standing Diflucan Partnership 
Negative
Positive
Lumbar puncture (+) Lumbar puncture (-)
Initiate ART
No uconazole
Cryptococcal antigen screening when
CD4+ T-lymphocyte count <100 cells/µL
•    Contact patient for urgent follow-up
•    Screen for symptoms of meningitis*
•    Check for special situations†
Symptomatic Asymptomatic‡
Start uconazole 1 200 mg daily and refer
immediately for lumbar puncture
Amphotericin B plus uconazole
800 mg daily for 2 weeks in hospital
Fluconazole 800 mg daily for
2 weeks as outpatient
‡A lumbar puncture may be considered, if
available
•    prior cryptococcal meningitis
•    pregnancy, or breastfeeding mother
•    clinical liver disease
†Special situations include:
*Symptomatic for meningitis if either of
the following is present:
•    headache
•    confusion
Start ART after 4 - 6 weeks of
antifungal therapy
Start ART after 2 weeks of
antifungal therapy
Fluconazole 400 mg daily for 2 months, then 200 mg daily
Continue uconazole for minimum of 1 year and discontinue
when patient has had two CD4+ counts >200 cells/µL taken at least 6 months
apart
Fig. 1. Cryptococcal screen-and-treat algorithm for antiretroviral therapy (ART)-naive adult patients with a CD4+ T-lymphocyte count <100 cells/µL 
(Govender et al.[24]).
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Programme and government procurement of relatively cheap, generic 
formulations. The WHO guidelines emphasise that patients receiving 
amphotericin B-containing induction-phase regimens should have 
access to a ‘minimum package of toxicity prevention, monitoring 
and management to minimise the serious amphotericin B-related 
toxicities particularly hypokalaemia and nephrotoxicity’.[20] In routine 
practice, amphotericin B-related toxicities are common. In a recent 
cross-sectional study at sentinel SA hospitals, 12% of patients with 
CM developed anaemia, 39% hypokalaemia and 30% nephrotoxicity 
during the course of induction-phase treatment with amphotericin B.[27] 
The SAHIVCS guidelines recommend that, among patients without pre-
existing renal impairment and hyperkalaemia, a litre of normal saline 
containing an ampoule of potassium chloride should be administered 
intravenously prior to each daily dose of amphotericin B and 
that pre-emptive oral potassium chloride and magnesium chloride 
supplements be prescribed for the duration of the amphotericin 
B-containing induction phase. The guidelines also recommend 
baseline and twice-weekly monitoring of serum potassium and 
creatinine, baseline and weekly monitoring of haemoglobin, daily 
monitoring of fluid input and output and appropriate management 
of electrolyte abnormalities for the duration of amphotericin B 
treatment. Raised intracranial pressure (ICP) should be excluded at 
the time of diagnosis of an episode of CM and considered during 
hospital admission if symptoms/signs of raised ICP recur. The latter 
requires pressure management with regular LPs. 
Timing of ART 
Determining the optimal time for starting ART involves a balancing 
act of its benefits compared with the risk of immune reconstitution 
inflammatory syndrome (IRIS).[28] In general, delaying ART among 
patients with low CD4+ counts is associated with a high mortality. 
Until recently, there has been very little evidence for the optimal 
time to start ART after the initiation of antifungal treatment for CM. 
Previously, most study protocols for clinical trials in SA, Uganda, 
Malawi and Thailand advocated ART initiation 2 - 6 weeks after 
starting antifungal therapy.[29] There have been four randomised 
trials that have tried to answer the question of optimal ART timing. 
Three of the trials were underpowered to provide definitive guidance 
on this issue and yielded very different results. The multi-site 
randomised controlled Cryptococcal Optimal ART Timing (COAT) 
trial showed that initiation of ART 1 - 2 weeks (n=88) v. 5 weeks 
after diagnosis (n=89) was associated with a significantly higher 
6-month mortality (hazard ratio for death 1.73 (95% confidence interval 
1.06 - 2.82)).[11] This finding applied to all categories of HIV-infected 
patients, including those with a CD4+ count <50 cells/µL. Therefore, 
the accepted, considered and safe approach is that ART be introduced 
4 - 6 weeks after antifungal therapy is started.[24]
Relapse of CM 
A culture-confirmed relapse episode should be treated similarly to 
an initial episode of CM. The cumulative incidence of a symptomatic 
relapse following an episode of CM is between 6% and 23%.[30] The 
potential reasons for a relapse include IRIS, inadequate secondary 
fluconazole prophylaxis, raised ICP despite fungal clearance or, 
uncommonly, fluconazole resistance. It is estimated that at least 
50 - 60% of patients will relapse without secondary prophylaxis 
and ART.[31] A study conducted in Cape Town over a 2-year period in 
57 patients with CM relapse found that 30 were not taking fluconazole; 
of these, 53% were non-adherent to therapy and 47% were discharged 
without being prescribed secondary prophylaxis or receiving it at 
the clinic.[31] These data suggest that major causes of inadequate 
secondary prophylaxis in SA are suboptimal patient adherence and 
non-prescription of fluconazole secondary prophylaxis. Improving 
the knowledge of patients and healthcare providers should help 
to address these problems. Two forms of cryptococcal IRIS are 
recognised: paradoxical IRIS and unmasking IRIS. Paradoxical 
IRIS is defined as the recurrence of symptoms/signs of a previously 
treated opportunistic infection (OI).[28,32] Paradoxical IRIS occurs 
in 6 - 45% of patients with prior CM.[28] After ART initiation, 
paradoxical IRIS may occur at a median of 1 - 2 months or, in some 
instances, 8 - 9 months later.[28] In cases of severe or refractory IRIS, 
corticosteroids may be used (starting dose of prednisone 1 mg/kg 
reduced over several weeks) in addition to therapeutic LPs. Raised 
ICP may be a presenting feature of paradoxical IRIS despite fungal 
Table 1. Management of an initial episode of cryptococcal meningitis among HIV-infected ART-naive adults 
Diagnosis • Confirm the diagnosis by LP and submit cerebrospinal fluid for a rapid test (either 
cryptococcal antigen or India ink test) and fungal culture
Raised intracranial pressure • Measure the opening pressure at the time of diagnostic LP (in the left lateral supine position)
• If the opening pressure is >25 cmH2O, remove 10 - 30 mL cerebrospinal fluid
• Repeat therapeutic LPs whenever the patient has symptoms/signs of raised intracranial 
pressure, e.g. headache, vomiting, 6th cranial nerve palsy (note: daily LPs may be required)
Induction-phase antifungal treatment • Prescribe amphotericin B deoxycholate 1 mg/kg/d and fluconazole 800 mg/d for 14 days 
Prevention and laboratory monitoring of 
amphotericin B toxicities
• Infuse 1 L normal saline containing 1 ampoule of potassium chloride over 2 hours before 
the amphotericin B infusion 
• Prescribe twice-daily oral potassium and daily oral magnesium supplementation
• Check creatinine and potassium (and magnesium, if test is available) at baseline and twice 
weekly
• Check haemoglobin at baseline and weekly
Outpatient management • Prescribe consolidation-phase treatment (fluconazole 400 mg/d)
• Ensure that the patient is appropriately counselled regarding the diagnosis and need to 
continue long-term fluconazole and start ART 
• Refer the patient to an ART clinic 
ART • Start ART 4 - 6 weeks after initiation of antifungal treatment 
ART = antiretroviral therapy; LP = lumbar puncture.
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clearance.[33] Raised ICP is a serious and often fatal complication of 
CM, which requires good pressure management with repeat LPs. A 
number of studies have shown that repeated LPs are associated with 
a decreased risk of acute mortality.[34,35] 
Discussion 
Despite the availability of ART, CM is associated with a high 
mortality – even with efficacious and prompt antifungal therapy. 
The induction-phase regimen should include a combination of 
amphotericin B and fluconazole. Access to flucytosine is limited 
because this agent is not registered in SA and only available on a 
compassionate basis. In conjunction with antifungal therapy, an 
important aspect of management includes adequate control of 
raised ICP, achieved by LPs performed daily until pressure has 
normalised and symptoms/signs have resolved. The administration of 
amphotericin B deoxycholate may lead to a number of complications, 
including renal toxicity, hypokalaemia and phlebitis; these need to be 
managed proactively. Tuberculosis and cryptococcal disease are often 
comorbid conditions[36] and their simultaneous management poses 
a challenge in terms of drug burden and drug-drug interactions. 
Furthermore, relapse following an initial episode is common and 
should prompt a full investigation to determine and manage the 
underlying cause. Although early HIV diagnosis and ART initiation 
before the onset of AIDS are major interventions needed to reduce 
the incidence of CM, the cryptococcal screen-and-treat intervention 
has the potential to reduce CM-associated mortality.
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